Glioblastoma has long confounded medicine not because surgeons cannot remove the tumor they can see, but because the cells they cannot see slip silently into healthy brain tissue and wait. A research team at the University of Bonn has built a model called Core2Edge — marrying patient-derived tumor organoids with actual human brain slices — to watch this invisible migration unfold, cell by cell, in human tissue for the first time. The work, published in Nature Protocols, does not yet offer a cure, but it offers something medicine has lacked: a true window into the moment recurrence begins.
New human tissue model reveals how glioblastoma cells infiltrate the brain
Glioblastoma patients face tumor recurrence within months despite multimodal therapy, with no current cure available.
Hidden cells remain, waiting to grow back into a new tumor.
Mark
Why does glioblastoma keep coming back if surgeons remove the whole tumor?
Mimi
Because the tumor doesn't stay in one place. Cells spread into the healthy brain tissue around it, far beyond what imaging can show. After surgery, those hidden cells are still there.
Luke
How far do they spread? Is there a distance we know?
Mimi
The source doesn't give a specific distance. It just says they migrate "far beyond the visible tumor."
Mark
So this new model—Core2Edge—it lets them see those hidden cells?
Mimi
Yes. They grow a tumor organoid from a patient's own tissue and place it into a slice of human brain. Then they watch how the tumor cells spread into the healthy tissue, cell by cell.
Luke
But is this actually what happens in a patient's brain, or is it a simplified version?
Mimi
That's the key question the researchers tested. They found that the model reproduces intratumoral heterogeneity—the genetic variation within the tumor—which is what you see in real patients.
Mark
What's intratumoral heterogeneity?
Mimi
Different cells within the same tumor have different genetic profiles. Some survive radiation and chemotherapy better than others. That's why tumors come back.
Luke
And Core2Edge can show which cells are which?
Mimi
Yes. They use spatial transcriptomics to map which genes are active in each cell and where that cell is located in the tissue.
Mark
Does this lead to new treatments?
Mimi
Not yet. But it identifies which cellular programs drive infiltration, which could point to new therapeutic targets.
Luke
One more thing—they're using brain tissue from surgery. Is there enough of it?
Mimi
The tissue is routinely removed during neurosurgery to access deeper regions. It would otherwise be discarded. So yes, there's a supply.
Il Polso
- Glioblastoma kills not through the tumor surgeons remove, but through the cells that escape it — infiltrating healthy brain tissue beyond the reach of imaging, surgery, or chemotherapy.
- Animal models have long been the only tool for studying this invasion, yet they fail to replicate the genetic complexity and behavior of human glioblastoma, leaving a critical gap in understanding.
- Core2Edge closes that gap by embedding patient-derived tumor organoids directly into human brain slices, then using high-resolution 3D microscopy and spatial transcriptomics to map each infiltrating cell and its genetic activity in real time.
- The model successfully reproduces the genetic diversity found in actual patient tumors, validating it as a faithful mirror of real disease rather than a laboratory approximation.
- Researchers now have a platform to identify which cellular programs drive recurrence and which targets might be blocked — while also reducing the field's dependence on animal experimentation.
Glioblastoma has long confounded medicine not because surgeons cannot remove the tumor they can see, but because the cells they cannot see slip silently into healthy brain tissue and wait. A research team at the University of Bonn has built a model called Core2Edge — marrying patient-derived tumor organoids with actual human brain slices — to watch this invisible migration unfold, cell by cell, in human tissue for the first time. The work, published in Nature Protocols, does not yet offer a cure, but it offers something medicine has lacked: a true window into the moment recurrence begins.
Glioblastoma is relentless not because surgeons fail, but because the tumor does not end where imaging says it does. Cells migrate silently into surrounding healthy brain tissue long before any scan can detect them. Surgery removes the visible mass; radiation and chemotherapy follow. And still, recurrence comes — often within months — because those hidden cells were never reached.
A team at the University of Bonn and University Hospital Bonn has built a model designed to study exactly those cells. Core2Edge places miniature tumors grown from freshly removed patient tissue directly into slices of human brain harvested during routine neurosurgery. Using high-resolution light-sheet fluorescence microscopy — which reconstructs tissue in three dimensions at single-cell resolution — researchers can watch individual glioblastoma cells infiltrate outward into the surrounding brain, tracing the earliest steps of an invasion that has until now been nearly impossible to observe in human tissue.
Seeing the cells move is only part of what Core2Edge offers. The team also applied spatial transcriptomics, mapping which genes are active in each cell and where that cell sits within the tissue. This matters because glioblastoma is not a uniform disease — even within one tumor, cells carry different genetic profiles and respond differently to treatment. This internal diversity is a central reason tumors return. Core2Edge captures that diversity directly in human tissue, revealing which cell populations occupy the infiltration zones and how they differ from one another.
Dr. Matthias Schneider, who leads the Brain Tumor Translational Research Group, describes the model as a way to study the cells no surgeon can reach. First author Ahmad Melhem, who co-developed Core2Edge during his doctoral work, emphasizes its ability to illuminate the earliest organizational steps of invasion. Dr. Anna-Laura Potthoff confirms that the model faithfully reproduces the genetic diversity seen in actual patient tumors — evidence that it reflects real biology rather than a simplified stand-in.
Published in Nature Protocols, the work points toward identifying therapeutic targets that might delay or prevent recurrence. It also carries a broader significance: because the brain tissue used comes from material routinely removed during neurosurgery and would otherwise be discarded, Core2Edge offers a scientifically rigorous and ethically grounded alternative to animal experiments — built entirely from what patients and surgeons already provide.
Glioblastoma is one of the most aggressive cancers known. Surgeons can remove the visible tumor. Radiation and chemotherapy follow. And still, patients face recurrence—often within months. The reason is both simple and devastating: glioblastoma cells do not stay put. They slip into the surrounding healthy brain tissue, spreading far beyond what any imaging can show. Once surgery ends, those hidden cells remain, waiting to grow back into a new tumor.
Understanding why this happens has been nearly impossible. Researchers cannot easily study the cells that escape into the brain without relying on animal models, which do not fully capture human biology. But a team at the University of Bonn and the University Hospital Bonn has developed a new approach. They call it Core2Edge, and it combines two things: miniature tumors grown from freshly removed patient tissue, and slices of actual human brain harvested during routine neurosurgery. By placing the tumor organoids directly into the brain tissue and watching what happens, they can track individual glioblastoma cells as they infiltrate outward, cell by cell, into regions far from the original tumor mass.
The visualization is extraordinarily detailed. The team uses high-resolution light-sheet fluorescence microscopy, a technique that scans tissue layer by layer and reconstructs three-dimensional images at single-cell resolution. Before scanning, they expand the tissue chemically to improve light penetration and reveal fine structures invisible at normal magnification. The result is a complete map of how tumor cells spread through human brain tissue—not a guess, not an animal proxy, but the actual invasion process as it occurs in human cells.
But seeing the cells is only part of the story. The researchers also applied spatial transcriptomics, a method that reveals which genes are active in each cell and exactly where that cell sits in the tissue. This matters because glioblastoma cells are not uniform. Even within a single tumor, different cells have different genetic profiles and different responses to treatment. Some survive radiation and chemotherapy more effectively than others. This variation—called intratumoral heterogeneity—is a major reason why tumors come back. Core2Edge can capture this heterogeneity directly in human tissue, showing which cell populations exist in the infiltration zones and how they differ from one another.
Dr. Matthias Schneider, deputy director of neurosurgery at the University Hospital Bonn and head of the Brain Tumor Translational Research Group, emphasizes what this means for the field. To understand why glioblastoma recurs, researchers need to study the cells that hide in the brain after surgery—the ones no surgeon can reach. Core2Edge makes that study possible in a human tissue model that mirrors what clinicians actually see in patients. Ahmad Melhem, the first author who co-developed the model as part of his doctoral work, notes that the approach provides a detailed view of the earliest steps of invasion and how tumor cells organize themselves as they infiltrate the brain.
Dr. Anna-Laura Potthoff, a neurosurgeon and clinician-scientist at the research group, confirms that Core2Edge reproduces the genetic diversity seen in actual patient tumors. This is crucial evidence that the model reflects real biology. The work, published in Nature Protocols, lays groundwork for identifying which cellular programs drive infiltration and which therapeutic targets might delay or prevent recurrence.
Beyond glioblastoma research, the model addresses a broader scientific concern. Because key aspects of glioblastoma biology—especially infiltration and genetic heterogeneity—can now be studied directly in human tissue, Core2Edge offers a scientifically and ethically compelling alternative to animal experiments. Researchers can answer critical questions about tumor behavior without relying on animal models that do not fully replicate human disease. The brain tissue used comes from material routinely removed during neurosurgery to access deeper brain regions—tissue that would otherwise be discarded. Nothing is wasted. Nothing is invented. The model is built from what patients and surgeons already provide.
Citazioni salienti
To understand why glioblastoma keeps coming back, we need to look closely at the tumor cells that remain hidden in the brain after surgery.— Dr. Matthias Schneider, deputy director of neurosurgery at University Hospital Bonn
Core2Edge recapitulates intratumoral heterogeneity. This provides further evidence that the model closely reflects the situation in patients.— Dr. Anna-Laura Potthoff, neurosurgeon and clinician-scientist at the Brain Tumor Translational Research Group
Vuoi la storia completa?
Leggi l'originale su Medical Xpress ↗
Science & Space